Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
Investors view quarterly updates from clinical-stage biotechs in a very different way than they do for other companies. The bottom line isn't nearly as important for these small biotechs as are pipeline progress and cash position.
That was certainly the case for Celldex Therapeutics (NASDAQ: CLDX) when it announced second-quarter results in August. And it's still true now, with Celldex reporting its third-quarter results before the market opened on Tuesday. Here are the highlights.
Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Aktie
33,20 €
-0,62 %
Die Community neigt bei Celldex Therapeutics zu Buy-Einschätzungen, mehr als zu Sell-Einschätzungen.
Für Celldex Therapeutics ergibt sich mit einem Kursziel von 56 € eine mögliche Steigerung von über 50% gegenüber 33.2 €.
